Midlife insulin resistance, APOE genotype, and late-life brain amyloid accumulation

Neurology
Laura L EkbladJuha O Rinne

Abstract

To examine whether midlife insulin resistance is an independent risk factor for brain amyloid accumulation in vivo after 15 years, and whether this risk is modulated by APOE ε4 genotype. This observational study examined 60 elderly volunteers without dementia (mean age at baseline 55.4 and at follow-up 70.9 years, 55.5% women) from the Finnish population-based, nationwide Health2000 study with [11C]Pittsburgh compound B-PET imaging in 2014-2016. The participants were recruited according to their homeostatic model assessment of insulin resistance (HOMA-IR) values in the year 2000, and their APOE ε4 genotype. The exposure group (IR+, n = 30) consisted of individuals with HOMA-IR >2.17 at baseline (highest tertile of the Health2000 study population), and the control group (IR-, n = 30) consisted of individuals with HOMA-IR <1.25 at baseline (lowest tertile). The groups were enriched for APOE ε4 carriers, resulting in 50% (n = 15) APOE ε4 carriers in both groups. Analyses were performed with multivariate logistic and linear regression. An amyloid-positive PET scan was found in 33.3% of the IR- group and 60.0% of the IR+ group (odds ratio 3.0, 95% confidence interval 1.1-8.9, p = 0.04). The increased risk was seen in carriers and no...Continue Reading

References

Sep 26, 1997·The Journal of Clinical Investigation·E FerranniniG Mingrone
Jul 1, 1997·Neurobiology of Aging·H Braak, E Braak
Jul 1, 1997·Neurobiology of Aging·W SilvermanJ Wegiel
Dec 22, 1999·Neurology·A OttM M Breteler
Sep 3, 2004·Journal of Lipid Research·Minna T JänisChristian Ehnholm
Oct 13, 2004·Neurology·Jose A LuchsingerRichard Mayeux
Jul 13, 2005·Neurology·M J ChandlerC M Cullum
Dec 20, 2005·Lancet Neurology·Geert Jan BiesselsPhilip Scheltens
Nov 30, 2006·Diabetes Care·Sara E YoungMark Carnemolla
Apr 11, 2008·Neurology·E RönnemaaL Kilander
Jun 6, 2009·European Journal of Nuclear Medicine and Molecular Imaging·Sargo AaltoJuha O Rinne
May 18, 2010·Neurobiology of Aging·Christopher C RoweVictor L Villemagne
Dec 1, 2010·Neurology·E M C SchrijversM M B Breteler
Sep 1, 2012·Journal of Alzheimer's Disease : JAD·Suzanne CraftLaura D Baker
Sep 28, 2013·European Journal of Pharmacology·Brenna CholertonSuzanne Craft
Jul 22, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Auriel A WilletteBarbara B Bendlin
May 20, 2015·JAMA : the Journal of the American Medical Association·Willemijn J JansenHenrik Zetterberg
Apr 12, 2017·JAMA : the Journal of the American Medical Association·Rebecca F GottesmanThomas H Mosley
Jun 7, 2017·Journal of Alzheimer's Disease : JAD·Rosanna TortelliGiancarlo Logroscino

❮ Previous
Next ❯

Citations

Aug 2, 2019·Nature Reviews. Neurology·Yu YamazakiGuojun Bu
Jul 6, 2019·Frontiers in Neuroscience·Sami GabboujTeemu Natunen
Sep 29, 2019·Journal of Alzheimer's Disease : JAD·Sini ToppalaJuha O Rinne
Jan 24, 2021·Molecular Neurobiology·Anit Tyagi, Subbiah Pugazhenthi
Jan 31, 2021·CNS Drugs·Manfred Hallschmid
Jul 6, 2021·Frontiers in Neuroscience·Ann M SaundersWilliam Kirby Gottschalk

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping

Software Mentioned

SAS JMP Pro
BrainNet Viewer
FreeSurfer

Related Concepts

Related Feeds

Alzheimer's Disease: APOE

Apolipoprotein E (APOE) polymorphic alleles are major genetic risk factors for Alzheimer's disease. Discover the latest research on APOE and other genetic determinants of Alzheimer's disease here.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

© 2022 Meta ULC. All rights reserved